01620: Targeting Immune Cells as a Novel Treatment for Canine Atopic Dermatitis
Grant Status: Closed
Introduction: T-cell receptor (TCR) peptides are known to have immunomodulatory and immunoregulatory properties. Use of TCR peptides for treating canine atopic dermatitis, a prevalent condition in dogs, was evaluated in this double blind, placebo controlled study.
Study Design and Methods: This was a prospective, multi-site, double-blind, randomized study that evaluated the clinical effects of TCR peptide in 62 client-owned dogs with persistent, severe, atopic dermatitis. Dogs were randomly allocated into 3 treatment groups, Group A (100mg), Group B (25mg) or Group C (placebo). Treatments were administered subcutaneously at baseline and Week 2, and dogs were evaluated for efficacy and safety at baseline, Week 2 and Week 6 using standardized score forms for itchiness, redness, abrasion, hair loss, and overall severity and adverse events. Complete blood counts, chemistry, and anti- TCR titer measurements were taken at baseline and Week 6.
Results: Group A had significant improvement (p Significant increases in anti-TCR titers at week 6 were detected in Group A (TCR 100mg) but not in other groups. There were no alterations in blood chemistry or hematology parameters in any group. Side effects were reported in only 6 of the 62 dogs, none serious.
Conclusions: Consistent with previous studies, the TCR peptide appears to have clinical benefits in dogs with signs of atopic dermatitis. The overall improvements were less than anticipated, and may be associated with a reduction in potency owing to a new peptide manufacturing process. TCR peptide therapy is well tolerated; no toxicity was detected. Further studies in optimizing the potency, manufacturing and dosage are warranted.
None at this time.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.